Drug Recalls
Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.
Ascend Laboratories, LLC
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and T…
Ascend Laboratories, LLC
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and T…
Cipla USA, Inc.
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
Cipla USA, Inc.
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
Cipla USA, Inc.
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
Lannett Company Inc.
Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.
Remifentanil hydrochloride for injection 1 mg/vial
Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…
Spiriva 18mcg capsule
Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Bell Pharmaceuticals, Inc
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
Reliance Life Sciences Private Limited
Lack of Sterility Assurance
Reliance Life Sciences Private Limited
Lack of Sterility Assurance
Reliance Life Sciences Private Limited
Lack of Sterility Assurance
Reliance Life Sciences Private Limited
Lack of Sterility Assurance
QuVa Pharma, Inc.
Failed Impurities/Degradation Specifications
JB Chemicals and Pharmaceuticals Ltd
Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP…